Source avec lien : MMWR. Morbidity and Mortality Weekly Report, 70(21), . 10.15585/mmwr.mm7021e3
Les vaccins COVID-19 sont un outil essentiel pour contrôler la pandémie mondiale en cours. Malgré le haut niveau d’efficacité du vaccin, un petit pourcentage de personnes entièrement vaccinées (c’est-à-dire ayant reçu toutes les doses recommandées d’un vaccin COVID-19 autorisé par la FDA) développera des infections symptomatiques ou asymptomatiques par le SRAS-CoV-2, le virus responsable du COVID-19 (2-8).
COVID-19 vaccines are a critical tool for controlling the ongoing global pandemic. Despite the high level of vaccine efficacy, a small percentage of fully vaccinated persons (i.e. received all recommended doses of an FDA-authorized COVID-19 vaccine) will develop symptomatic or asymptomatic infections with SARS-CoV-2, the virus that causes COVID-19 (2–8). CDC is working with state and territorial health departments to investigate SARS-CoV-2 infections among persons who are fully vaccinated and to monitor trends in case characteristics and SARS-CoV-2 variants identified from persons with these infections. For this surveillance, a vaccine breakthrough infection is defined as the detection of SARS-CoV-2 RNA or antigen in a respiratory specimen collected from a person ≥14 days after receipt of all recommended doses of an FDA-authorized COVID-19 vaccine. State health departments voluntarily report vaccine breakthrough infections to CDC.† When possible, genomic sequencing is performed on respiratory specimens that test positive for SARS-CoV-2 RNA (9).